H100Plus Hemoglobin Testing System
Shenzhen Lifotronic Technology Co., Ltd. · Decision date Oct 2, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-02 for the H100Plus Hemoglobin Testing System, submitted by Shenzhen Lifotronic Technology Co., Ltd. under 510(k) number K260468. The device falls under the classification name Hemoglobin A1c Test System, regulation number 862.1373, product code PDJ with subsequent product code LCP, in the Clinical Chemistry specialty and review panel. The record lists the application as received 02/12/2026, a traditional review not conducted by a third party, not a combination product, and with no authorized predetermined change control plan. SESE denotes 510(k) clearance, not PMA approval.
A separate CLIA record, CR260089, lists the same device and applicant with parent K260468 for the analyte Glycosylated Hemoglobin (Hgb A1c), General Chemistry specialty, MODERATE complexity, effective 10/23/2026. The source does not include the decision summary, indications for use, performance data, or any predicate device, so the basis for substantial equivalence and the cleared labeling remain unknown. No clinical or legal conclusion about the device's performance should be drawn from these records alone.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Oct 2, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260468
- Regulatory pathway
- 510(k) premarket notification
- Product code
- PDJ
- Decision code
- SESE
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Hemoglobin A1c Test System.
- Product code
- PDJ
- FDA device class
- 2
FDA decision timeline
K260468 received
Application receipt date recorded by FDA.
K260468 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Shenzhen Lifotronic Technology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Shenzhen
Sources and methodology
- Original FDA record: K260468
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records